Modified release fixed dose combination product with two poorly soluble drug substances

OSD

A sponsor company contracted Recipharm to develop a modified release fixed dose combination (FDC) product of existing molecules for treatment of a neurodegenerative disorder. There are two poorly soluble molecules in this combination product: one is a BCS class II molecule (A); and the other is a BCS class IV molecule (B). The concentration of both molecules is in a ratio of 1:10 in the existing formulation and the sponsor wished to develop a formulation with a similar rate of dissolution of both molecules.

First Name

Last Name

Company

Where are you based?

State/Province

I agree that Recipharm registers the above information and gives me information about services and products via email. Read more about our Privacy Policy

Hidden OSD

Hidden SFF

Hidden ADS

Hidden BU not set